RE:DxTM sales blip makes revenues look flat2024 will be back to creating new record highs for revenue after absorbing the lost DxTM revenue. It will be back to clear signs of growth which should help build momentum for the stock as biotech may also be back in favor with falling interest rates. There's one more month of tax loss selling too before all eyes are on the future of a company once again clearly growing with the Kinlytic opportunity too.
lscfa wrote:
| Qtr ending | Antigen | QAP | DxTM | Royalties/Licensing | Total Revenue |
| Sep 23 (e) | 2,500,000 | 1,500,000 | 0 | 1,400,000 | 5,400,000 |
| Jun 23 | 2,608,521 | 1,456,905 | 0 | 1,464,726 | 5,530,152 |
| Mar 23 | 3,004,730 | 1,101,684 | 0 | 111,910 | 4,218,324 |
| Dec 22 | 1,003,807 | 1,333,503 | 0 | 164,762 | 2,502,072 |
| Sept 22 | 2,629,901 | 1,601,900 | 0 | 97,300 | 4,329,101 |
| Jun 22 | 2,283,621 | 1,305,896 | 1,326,410 | 95,099 | 5,011,026 |
| Mar 22 | 1,607,970 | 1,318,382 | 1,860,704 | 93,508 | 4,880,564 |
| Dec 21 | 1,766,416 | 1,149,151 | 1,817,245 | 122,787 | 4,855,599 |
| Sep 21 | 2,020,861 | 1,195,545 | 2,327,600 | 85,689 | 5,629,695 |
| Jun 21 | 2,398,969 | 1,051,617 | 1,924,300 | 76,948 | 5,451,834 |
| Mar 21 | 2,524,363 | 1,495,088 | 255,000 | 79,322 | 4,353,773 |
| Dec 20 | 2,137,829 | 962,421 | 0 | 57,409 | 3,157,659 |
| Sept 20 | 2,151,767 | 505,898 | 0 | 48,067 | 2,705,732 |
| Jun 20 | 2,245,912 | 570,148 | 0 | 82,218 | 2,898,278 |
| Mar 20 | 2,357,972 | 425,837 | 0 | 90,687 | 2,874,496 |
| Dec 19 | 1,946,459 | 26,114 | 0 | 73,775 | 2,046,348 |